Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Will Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Rule This Multibillion-Dollar Market?

Page 1 of 2

Multiple sclerosis, or MS, is a terrible disease — but the market for MS therapies sure has gotten exciting recently.

Back in 2011, generic drug giant Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) dominated the MS field, riding the coattails of its Copaxone medication to success. Since then, a whole lot has changed: With the advent of oral MS therapies, the market’s undergone a facelift. Companies pour resources into finding new therapies for a market predicted to swell to $14 billion by 2015. The question arises: Just which company is at the top of the MS market going forward?

Teva’s old reliable
Before we get too enthusiastic about new treatments, don’t sign off on Teva. Even with competition sprouting up all over the place, Copaxone still hasn’t relinquished a powerful hold on the industry.

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)The drug pulled in nearly $4 billion in sales over the course of 2012, making up 20% of Teva’s total revenue. That figure also represented year-over-year growth of 12% as Teva’s managed to continue pumping its biggest branded drug despite new competition. This isn’t a drug anywhere near ceding control of the industry just yet.

However, even Teva’s cautious about Copaxone’s future. Teva’s head of global brands admitted last year that 2012 would likely see the height of the drug’s sales, projecting Copaxone’s revenue to fall to $2.7 billion by 2015, the year its patent expires. Teva’s therapy is already stalling in the U.S.: Copaxone recorded just 4% sales growth domestically in 2012, driven mostly by price increases. While sales outside the U.S. jumped significantly, international revenues make up only a little more than 25% of the drug’s total revenue.

Copaxone’s not doomed by any measure — as of the third quarter of 2012, the drug held a 40% market share in the U.S. — but it’s critical for investors to understand that it’s facing a long downslide in years ahead. With companies such as Mylan Inc. (NASDAQ:MYL) circling to launch generic competitors after Copaxone’s patent expires, 2016 could be a tough year for Teva investors.

So, just which products and companies are stepping in to fill the void?

Competitors abound
While oral therapies are the new face of MS medications, there are plenty of injectable medicines still vying for sales with Copaxone. Merck Serono and Pfizer Inc. (NYSE:PFE)‘s Rebif treatment continues to do well, recording sales of $670 million for the former in the third quarter of 2012. Pfizer reported Rebif growing in the U.S., a good sign for the product considering Copaxone’s domestic stall.

Biogen Idec Inc. (NASDAQ:BIIB) also markets successful injectable therapies. The company’s Avonex continues to be the best competitor to Copaxone, posting 2012 full-year sales of $2.9 billion — an 8% year-over-year growth. Biogen’s got a strong handle on the market, with fellow MS drug Tysabri posting 5% year-over-year sales growth to reach $1.1 billion in full-year revenue. Biogen managed to extend Avonex’s patent protection from its original expiration date this year all the way to 2026; however, that’s being challenged, and expect some Avonex sales to decline with the rise of oral therapies.

Gilenya, Novartis AG (ADR) (NYSE:NVS)‘  forerunner of the oral MS drug market, first rose to prominence with its FDA approval in late 2010. The drug’s had safety concerns since its launch — 11 patients died  at one point, leading to an investigation eventually cleared up  by regulators — but since then, Gilenya’s been on a roll. The drug hit blockbuster status for Novartis in 2012 with sales of $1.2 billion over the full year. Analysts expect peak sales from $2.1 billion all the way to $3.5 billion for the drug in coming years, with safety concerns weighing on the lower estimates. Still, expect Gilenya to be a major player in the MS market.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!